249 related articles for article (PubMed ID: 34552066)
1. Super-enhancer-based identification of a BATF3/IL-2R-module reveals vulnerabilities in anaplastic large cell lymphoma.
Liang HC; Costanza M; Prutsch N; Zimmerman MW; Gurnhofer E; Montes-Mojarro IA; Abraham BJ; Prokoph N; Stoiber S; Tangermann S; Lobello C; Oppelt J; Anagnostopoulos I; Hielscher T; Pervez S; Klapper W; Zammarchi F; Silva DA; Garcia KC; Baker D; Janz M; Schleussner N; Fend F; Pospíšilová Š; Janiková A; Wallwitz J; Stoiber D; Simonitsch-Klupp I; Cerroni L; Pileri S; de Leval L; Sibon D; Fataccioli V; Gaulard P; Assaf C; Knörr F; Damm-Welk C; Woessmann W; Turner SD; Look AT; Mathas S; Kenner L; Merkel O
Nat Commun; 2021 Sep; 12(1):5577. PubMed ID: 34552066
[TBL] [Abstract][Full Text] [Related]
2. IL-2/IL-2R signaling and IL-2Rα-targeted therapy in anaplastic large cell lymphoma.
Liang HC
Pathologie (Heidelb); 2022 Aug; 43(Suppl 1):25-30. PubMed ID: 36094651
[TBL] [Abstract][Full Text] [Related]
3. An oncogenic axis of STAT-mediated BATF3 upregulation causing MYC activity in classical Hodgkin lymphoma and anaplastic large cell lymphoma.
Lollies A; Hartmann S; Schneider M; Bracht T; Weiß AL; Arnolds J; Klein-Hitpass L; Sitek B; Hansmann ML; Küppers R; Weniger MA
Leukemia; 2018 Jan; 32(1):92-101. PubMed ID: 28659618
[TBL] [Abstract][Full Text] [Related]
4. The AP-1-BATF and -BATF3 module is essential for growth, survival and TH17/ILC3 skewing of anaplastic large cell lymphoma.
Schleussner N; Merkel O; Costanza M; Liang HC; Hummel F; Romagnani C; Durek P; Anagnostopoulos I; Hummel M; Jöhrens K; Niedobitek A; Griffin PR; Piva R; Sczakiel HL; Woessmann W; Damm-Welk C; Hinze C; Stoiber D; Gillissen B; Turner SD; Kaergel E; von Hoff L; Grau M; Lenz G; Dörken B; Scheidereit C; Kenner L; Janz M; Mathas S
Leukemia; 2018 Sep; 32(9):1994-2007. PubMed ID: 29588546
[TBL] [Abstract][Full Text] [Related]
5. Oncogenic role of miR-155 in anaplastic large cell lymphoma lacking the t(2;5) translocation.
Merkel O; Hamacher F; Griessl R; Grabner L; Schiefer AI; Prutsch N; Baer C; Egger G; Schlederer M; Krenn PW; Hartmann TN; Simonitsch-Klupp I; Plass C; Staber PB; Moriggl R; Turner SD; Greil R; Kenner L
J Pathol; 2015 Aug; 236(4):445-56. PubMed ID: 25820993
[TBL] [Abstract][Full Text] [Related]
6. CD30 Downregulation, MMAE Resistance, and MDR1 Upregulation Are All Associated with Resistance to Brentuximab Vedotin.
Chen R; Hou J; Newman E; Kim Y; Donohue C; Liu X; Thomas SH; Forman SJ; Kane SE
Mol Cancer Ther; 2015 Jun; 14(6):1376-84. PubMed ID: 25840583
[TBL] [Abstract][Full Text] [Related]
7. Identification of differential and functionally active miRNAs in both anaplastic lymphoma kinase (ALK)+ and ALK- anaplastic large-cell lymphoma.
Merkel O; Hamacher F; Laimer D; Sifft E; Trajanoski Z; Scheideler M; Egger G; Hassler MR; Thallinger C; Schmatz A; Turner SD; Greil R; Kenner L
Proc Natl Acad Sci U S A; 2010 Sep; 107(37):16228-33. PubMed ID: 20805506
[TBL] [Abstract][Full Text] [Related]
8. Analysis and therapeutic targeting of the IL-1R pathway in anaplastic large cell lymphoma.
Song Z; Wu W; Wei W; Xiao W; Lei M; Cai KQ; Huang DW; Jeong S; Zhang JP; Wang H; Kadin ME; Waldmann TA; Staudt LM; Nakagawa M; Yang Y
Blood; 2023 Oct; 142(15):1297-1311. PubMed ID: 37339580
[TBL] [Abstract][Full Text] [Related]
9. Cytokine receptor signaling is required for the survival of ALK- anaplastic large cell lymphoma, even in the presence of JAK1/STAT3 mutations.
Chen J; Zhang Y; Petrus MN; Xiao W; Nicolae A; Raffeld M; Pittaluga S; Bamford RN; Nakagawa M; Ouyang ST; Epstein AL; Kadin ME; Del Mistro A; Woessner R; Jaffe ES; Waldmann TA
Proc Natl Acad Sci U S A; 2017 Apr; 114(15):3975-3980. PubMed ID: 28356514
[TBL] [Abstract][Full Text] [Related]
10. STAT1 is phosphorylated and downregulated by the oncogenic tyrosine kinase NPM-ALK in ALK-positive anaplastic large-cell lymphoma.
Wu C; Molavi O; Zhang H; Gupta N; Alshareef A; Bone KM; Gopal K; Wu F; Lewis JT; Douglas DN; Kneteman NM; Lai R
Blood; 2015 Jul; 126(3):336-45. PubMed ID: 25921060
[TBL] [Abstract][Full Text] [Related]
11. A novel patient-derived tumorgraft model with TRAF1-ALK anaplastic large-cell lymphoma translocation.
Abate F; Todaro M; van der Krogt JA; Boi M; Landra I; Machiorlatti R; Tabbò F; Messana K; Abele C; Barreca A; Novero D; Gaudiano M; Aliberti S; Di Giacomo F; Tousseyn T; Lasorsa E; Crescenzo R; Bessone L; Ficarra E; Acquaviva A; Rinaldi A; Ponzoni M; Longo DL; Aime S; Cheng M; Ruggeri B; Piccaluga PP; Pileri S; Tiacci E; Falini B; Pera-Gresely B; Cerchietti L; Iqbal J; Chan WC; Shultz LD; Kwee I; Piva R; Wlodarska I; Rabadan R; Bertoni F; Inghirami G;
Leukemia; 2015 Jun; 29(6):1390-401. PubMed ID: 25533804
[TBL] [Abstract][Full Text] [Related]
12. Dependency on the TYK2/STAT1/MCL1 axis in anaplastic large cell lymphoma.
Prutsch N; Gurnhofer E; Suske T; Liang HC; Schlederer M; Roos S; Wu LC; Simonitsch-Klupp I; Alvarez-Hernandez A; Kornauth C; Leone DA; Svinka J; Eferl R; Limberger T; Aufinger A; Shirsath N; Wolf P; Hielscher T; Sternberg C; Aberger F; Schmoellerl J; Stoiber D; Strobl B; Jäger U; Staber PB; Grebien F; Moriggl R; Müller M; Inghirami GG; Sanda T; Look AT; Turner SD; Kenner L; Merkel O
Leukemia; 2019 Mar; 33(3):696-709. PubMed ID: 30131584
[TBL] [Abstract][Full Text] [Related]
13. STAT3 couples activated tyrosine kinase signaling to the oncogenic core transcriptional regulatory circuitry of anaplastic large cell lymphoma.
Prutsch N; He S; Berezovskaya A; Durbin AD; Dharia NV; Maher KA; Matthews JD; Hare L; Turner SD; Stegmaier K; Kenner L; Merkel O; Look AT; Abraham BJ; Zimmerman MW
Cell Rep Med; 2024 Mar; 5(3):101472. PubMed ID: 38508140
[TBL] [Abstract][Full Text] [Related]
14. The ALK inhibitor ASP3026 eradicates NPM-ALK⁺ T-cell anaplastic large-cell lymphoma in vitro and in a systemic xenograft lymphoma model.
George SK; Vishwamitra D; Manshouri R; Shi P; Amin HM
Oncotarget; 2014 Jul; 5(14):5750-63. PubMed ID: 25026277
[TBL] [Abstract][Full Text] [Related]
15. Anaplastic lymphoma kinase-positive anaplastic large cell lymphoma: current and future perspectives in adult and paediatric disease.
Eyre TA; Khan D; Hall GW; Collins GP
Eur J Haematol; 2014 Dec; 93(6):455-68. PubMed ID: 24766435
[TBL] [Abstract][Full Text] [Related]
16. Prognostic significance and therapeutic potential of the activation of anaplastic lymphoma kinase/protein kinase B/mammalian target of rapamycin signaling pathway in anaplastic large cell lymphoma.
Gao J; Yin M; Zhu Y; Gu L; Zhang Y; Li Q; Jia C; Ma Z
BMC Cancer; 2013 Oct; 13():471. PubMed ID: 24112608
[TBL] [Abstract][Full Text] [Related]
17. Complete response in a critically ill patient with ALK-negative anaplastic large cell lymphoma treated with single agent brentuximab-vedotin.
Oregel KZ; Everett E; Zhang X; Nagaraj G
Expert Rev Anticancer Ther; 2016; 16(3):279-83. PubMed ID: 26809026
[TBL] [Abstract][Full Text] [Related]
18. CD8 expression in anaplastic large cell lymphoma correlates with noncommon morphologic variants and T-cell antigen expression suggesting biological differences with CD8-negative anaplastic large cell lymphoma.
Shen J; Medeiros LJ; Li S; Wang SA; Lin P; Khanlari M; Iyer SP; Yin CC; Tang G; Jorgensen JL; Hu S; Miranda RN; Xu J
Hum Pathol; 2020 Apr; 98():1-9. PubMed ID: 32032618
[TBL] [Abstract][Full Text] [Related]
19. Targeting autophagy enhances the anti-tumoral action of crizotinib in ALK-positive anaplastic large cell lymphoma.
Mitou G; Frentzel J; Desquesnes A; Le Gonidec S; AlSaati T; Beau I; Lamant L; Meggetto F; Espinos E; Codogno P; Brousset P; Giuriato S
Oncotarget; 2015 Oct; 6(30):30149-64. PubMed ID: 26338968
[TBL] [Abstract][Full Text] [Related]
20. CD30 Regulation of IL-13-STAT6 Pathway in Breast Implant-Associated Anaplastic Large Cell Lymphoma.
Kadin ME; Morgan J; Wei W; Song Z; Yang Y
Aesthet Surg J; 2023 Feb; 43(2):137-146. PubMed ID: 35999655
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]